{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:56:46Z","timestamp":1792522606998,"version":"4.5.0"},"reference-count":129,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2019,2,14]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Alzheimer\u2019s disease (AD) is an age-related progressive neurodegenerative disorder,\ncharacterized by the deposition of amyloid-\u03b2 within the brain parenchyma resulting in a significant\ndecline in cognitive functions. The pathophysiological conditions of the disease are recognized by\nthe perturbation of synaptic function, energy and lipid metabolism. In Addition deposition of amyloid\nplaques also triggers inflammation upon the induction of microglia. Peroxisome proliferatoractivated\nreceptors (PPARs) are ligand-activated transcription factors known to play important role\nin the regulation of glucose absorption, homeostasis of lipid metabolism and are further known to\ninvolved in repressing the expression of genes related to inflammation. Therefore, agonists of this\nreceptor represent an attractive therapeutic target for AD. Recently, both clinical and preclinical\nstudies showed that use of Peroxisome proliferator-activated receptor gamma (PPAR\u03b3) agonist\nimproves both learning and memory along with other AD related pathology. Thus, PPAR\u03b3 signifies\na significant new therapeutic target in treating AD. In this review, we have shed some light on the\nrecent progress of how, PPAR\u03b3 agonist selectively modulated different cellular targets in AD and\nits amazing potential in the treatment of AD.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570159x16666180828100002","type":"journal-article","created":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T12:03:16Z","timestamp":1535457796000},"page":"232-246","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer's Disease: An Update"],"prefix":"10.2174","volume":"17","author":[{"given":"Mahmood Ahmad","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Biochemistry, University College of Medical Sciences and GTB Hospital, University of Delhi, Dilshad Garden, Delhi 110095, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qamre","family":"Alam","sequence":"additional","affiliation":[{"name":"King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 80216, Jeddah 21589, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Absarul","family":"Haque","sequence":"additional","affiliation":[{"name":"King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 80216, Jeddah 21589, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ashafaq","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Jahir","family":"Khan","sequence":"additional","affiliation":[{"name":"School of Biotechnology, Jawaharlal Nehru University, New Delhi 110067, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam Md","family":"Ashraf","sequence":"additional","affiliation":[{"name":"King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 80216, Jeddah 21589, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahboob","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Hind Institute of Medical Sciences, Sitapur-2613013, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","volume":"80","author":"Hebert L.E.","year":"2013","unstructured":"Hebert LE, Weuve J, Scherr PA, Evans DA.  Alzheimer disease in the United States (2010-2050) estimated using the 2010 census.","journal-title":"Neurology"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMra0909142","volume":"362","author":"Querfurth H.W.","year":"2010","unstructured":"Querfurth HW, LaFerla FM.  Alzheimer\u2019s disease.","journal-title":"N Engl J Med"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/hmg\/ddl066","volume":"15","author":"Manczak M.","year":"2006","unstructured":"Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH.  Mitochondria are a direct site of A beta accumulation in Alzheimer\u2019s disease neurons: implications for free radical generation and oxidative damage in disease progression.","journal-title":"Hum Mol Genet"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.molmed.2007.12.002","volume":"14","author":"Reddy P.H.","year":"2008","unstructured":"Reddy PH, Beal MF.  Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer\u2019s disease.","journal-title":"Trends Mol Med"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.exger.2008.06.006","volume":"44","author":"Fratiglioni L.","year":"2009","unstructured":"Fratiglioni L, Qiu C.  Prevention of common neurodegenerative disorders in the elderly.","journal-title":"Exp Gerontol"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.nbd.2009.10.006","volume":"37","author":"Cameron B.","year":"2010","unstructured":"Cameron B, Landreth GE.  Inflammation, microglia, and Alzheimer\u2019s disease.","journal-title":"Neurobiol Dis"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/14728222.2011.594043","volume":"15","author":"Mandrekar-Colucci S.","year":"2011","unstructured":"Mandrekar-Colucci S, Landreth GE.  Nuclear receptors as therapeutic targets for Alzheimer\u2019s disease.","journal-title":"Expert Opin Ther Targets"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s12035-013-8435-5","volume":"48","author":"Zolezzi J.M.","year":"2013","unstructured":"Zolezzi JM, Inestrosa NC.  Peroxisome proliferator-activated receptors and Alzheimer\u2019s disease: hitting the blood-brain barrier.","journal-title":"Mol Neurobiol"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bcp.2014.07.018","volume":"92","author":"Wang L.","year":"2014","unstructured":"Wang L, Waltenberger B, Pferschy-Wenzig EM, Blunder M, Liu X, Malainer C, Blazevic T, Schwaiger S, Rollinger JM, Heiss EH, Schuster D, Kopp B, Bauer R, Stuppner H, Dirsch VM, Atanasov AG.  Natural product agonists of peroxisome proliferator-activated receptor gamma (PPAR\u03b3): a review.","journal-title":"Biochem Pharmacol"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.cell.2006.06.049","volume":"126","author":"Bookout A.L.","year":"2006","unstructured":"Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ.  Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network.","journal-title":"Cell"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2174\/092986709787458399","volume":"16","author":"Shie F.S.","year":"2009","unstructured":"Shie FS, Nivison M, Hsu PC, Montine TJ.  Modulation of microglial innate immunity in Alzheimer\u2019s disease by activation of peroxisome proliferator-activated receptor gamma.","journal-title":"Curr Med Chem"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ana.10206","volume":"51","author":"Feinstein D.L.","year":"2002","unstructured":"Feinstein DL, Galea E, Gavrilyuk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, Landreth GE, Pershadsingh HA, Weinberg G, Heneka MT.  Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis.","journal-title":"Ann Neurol"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10059-012-2297-y","volume":"33","author":"Choi J.M.","year":"2012","unstructured":"Choi JM, Bothwell AL.  The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases.","journal-title":"Mol Cells"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0092-8674(00)81574-3","volume":"93","author":"Nagy L.","year":"1998","unstructured":"Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM.  Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma.","journal-title":"Cell"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2217\/fca.10.86","volume":"6","author":"Azhar S.","year":"2010","unstructured":"Azhar S.  Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease.","journal-title":"Future Cardiol"},{"key":"ref=16","first-page":"305","volume":"27","author":"Scheen A.J.","year":"2001","unstructured":"Scheen AJ.  Thiazolidinediones and liver toxicity.","journal-title":"Diabetes Metab"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s12035-014-8743-4","volume":"51","author":"Kummer M.P.","year":"2015","unstructured":"Kummer MP, Schwarzenberger R, Sayah-Jeanne S, Dubernet M, Walczak R, Hum DW, Schwartz S, Axt D, Heneka MT.  Pan-PPAR modulation effectively protects APP\/PS1 mice from amyloid deposition and cognitive deficits.","journal-title":"Mol Neurobiol"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.amjcard.2010.08.048","volume":"107","author":"Marketou M.E.","year":"2011","unstructured":"Marketou ME, Kontaraki JE, Tsakountakis NA, Zacharis EA, Kochiadakis GE, Arfanakis DA, Parthenakis F, Chlouverakis G, Vardas PE.  Differential effect of telmisartan and amlodipine on monocyte chemoattractant protein-1 and peroxisome proliferator-activated receptor-gamma gene expression in peripheral monocytes in patients with essential hypertension.","journal-title":"Am J Cardiol"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejphar.2010.10.081","volume":"652","author":"Sukumaran V.","year":"2011","unstructured":"Sukumaran V, Watanabe K, Veeraveedu PT, Ma M, Gurusamy N, Rajavel V, Suzuki K, Yamaguchi K, Kodama M, Aizawa Y.  Telmisartan ameliorates experimental autoimmune myocarditis associated with inhibition of inflammation and oxidative stress.","journal-title":"Eur J Pharmacol"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1248\/bpb.b12-00387","volume":"35","author":"Shindo T.","year":"2012","unstructured":"Shindo T, Takasaki K, Uchida K, Onimura R, Kubota K, Uchida N, Irie K, Katsurabayashi S, Mishima K, Nishimura R, Fujiwara M, Iwasaki K.  Ameliorative effects of telmisartan on the inflammatory response and impaired spatial memory in a rat model of Alzheimer\u2019s disease incorporating additional cerebrovascular disease factors.","journal-title":"Biol Pharm Bull"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/1470320312459977","volume":"14","author":"Singh B.","year":"2013","unstructured":"Singh B, Sharma B, Jaggi AS, Singh N.  Attenuating effect of lisinopril and telmisartan in intracerebroventricular streptozotocin induced experimental dementia of Alzheimer\u2019s disease type: possible involvement of PPAR-\u03b3 agonistic property.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/HYPERTENSIONAHA.109.136879","volume":"54","author":"Tsukuda K.","year":"2009","unstructured":"Tsukuda K, Mogi M, Iwanami J, Min LJ, Sakata A, Jing F, Iwai M, Horiuchi M.  Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation.","journal-title":"Hypertension"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.pharmthera.2005.10.009","volume":"111","author":"Guo L.","year":"2006","unstructured":"Guo L, Tabrizchi R.  Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance.","journal-title":"Pharmacol Ther"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0955-0674(98)80138-5","volume":"10","author":"Fajas L.","year":"1998","unstructured":"Fajas L, Fruchart JC, Auwerx J.  Transcriptional control of adipogenesis.","journal-title":"Curr Opin Cell Biol"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/nature07202","volume":"454","author":"Bensinger S.J.","year":"2008","unstructured":"Bensinger SJ, Tontonoz P.  Integration of metabolism and inflammation by lipid-activated nuclear receptors.","journal-title":"Nature"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.brainres.2006.03.114","volume":"1093","author":"Chu K.","year":"2006","unstructured":"Chu K, Lee ST, Koo JS, Jung KH, Kim EH, Sinn DI, Kim JM, Ko SY, Kim SJ, Song EC, Kim M, Roh JK.  Peroxisome proliferator-activated receptor-gamma-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia.","journal-title":"Brain Res"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.pbb.2013.11.027","volume":"117","author":"Liu Y.W.","year":"2014","unstructured":"Liu YW, Zhu X, Zhang L, Lu Q, Zhang F, Guo H, Yin XX.  Cerebroprotective effects of ibuprofen on diabetic encephalopathy in rats.","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.nbd.2014.08.011","volume":"71","author":"Pisanu A.","year":"2014","unstructured":"Pisanu A, Lecca D, Mulas G, Wardas J, Simbula G, Spiga S, Carta AR.  Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-\u03b3 agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson\u2019s disease.","journal-title":"Neurobiol Dis"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"549691","DOI":"10.1155\/2015\/549691","volume":"2015","author":"Croasdell A.","year":"2015","unstructured":"Croasdell A, Duffney PF, Kim N, Lacy SH, Sime PJ, Phipps RP.  PPAR\u03b3 and the Innate Immune System Mediate the Resolution of Inflammation.","journal-title":"PPAR Res"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"32681","DOI":"10.1074\/jbc.M002577200","volume":"275","author":"Chung S.W.","year":"2000","unstructured":"Chung SW, Kang BY, Kim SH, Pak YK, Cho D, Trinchieri G, Kim TS.  Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages  direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B.","journal-title":"J Biol Chem"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nature03988","volume":"437","author":"Pascual G.","year":"2005","unstructured":"Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG, Glass CK.  A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma.","journal-title":"Nature"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/34184","volume":"391","author":"Jiang C.","year":"1998","unstructured":"Jiang C, Ting AT, Seed B.  PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines.","journal-title":"Nature"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0165-5728(00)00291-5","volume":"109","author":"O\u2019Barr S.","year":"2000","unstructured":"O\u2019Barr S, Cooper NR.  The C5a complement activation peptide increases IL-1beta and IL-6 release from amyloid-beta primed human monocytes: implications for Alzheimer\u2019s disease.","journal-title":"J Neuroimmunol"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/glia.1072","volume":"35","author":"Lue L.F.","year":"2001","unstructured":"Lue LF, Rydel R, Brigham EF, Yang LB, Hampel H, Murphy GM, Brachova L, Yan SD, Walker DG, Shen Y, Rogers J.  Inflammatory repertoire of Alzheimer\u2019s disease and nondemented elderly microglia","journal-title":"Glia"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2174\/138161208784480171","volume":"14","author":"Hoozemans J.J.","year":"2008","unstructured":"Hoozemans JJ, Rozemuller JM, van Haastert ES, Veerhuis R, Eikelenboom P.  Cyclooxygenase-1 and -2 in the different stages of Alzheimer\u2019s disease pathology.","journal-title":"Curr Pharm Des"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"10117","DOI":"10.1523\/JNEUROSCI.5268-11.2012","volume":"32","author":"Mandrekar-Colucci S.","year":"2012","unstructured":"Mandrekar-Colucci S, Karlo JC, Landreth GE.  Mechanisms underlying the rapid peroxisome proliferator-activated receptor-\u03b3-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer\u2019s disease.","journal-title":"J Neurosci"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"21591","DOI":"10.1074\/jbc.M115.652008","volume":"290","author":"Skerrett R.","year":"2015","unstructured":"Skerrett R, Pellegrino MP, Casali BT, Taraboanta L, Landreth GE.  Combined liver X receptor\/peroxisome proliferator-activated receptor \u03b3 agonist treatment reduces amyloid \u03b2 levels and improves behavior in amyloid precursor protein\/presenilin 1 mice.","journal-title":"J Biol Chem"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"17321","DOI":"10.1523\/JNEUROSCI.1569-12.2012","volume":"32","author":"Yamanaka M.","year":"2012","unstructured":"Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT.  PPAR\u03b3\/RXR\u03b1-induced and CD36-mediated microglial amyloid-\u03b2 phagocytosis results in cognitive improvement in amyloid precursor protein\/presenilin 1 mice.","journal-title":"J Neurosci"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/npp.2010.32","volume":"35","author":"Escribano L.","year":"2010","unstructured":"Escribano L, Sim\u00f3n AM, Gimeno E, Cuadrado-Tejedor M.  L\u00f3pez de, Maturana, R.; Garc\u00eda-Osta, A. Ricobaraza, A.; P\u00e9rez-Mediavilla, A.; Del, R\u00edo, J.; Frechilla, D. Rosiglitazone rescues memory impairment in Alzheimer\u2019s transgenic mice: mechanisms involving a reduced amyloid and tau pathology.","journal-title":"Neuropsychopharmacol"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11481-011-9282-7","volume":"7","author":"O\u2019Reilly J.A.","year":"2012","unstructured":"O\u2019Reilly JA, Lynch M.  Rosiglitazone improves spatial memory and decreases insoluble A\u03b2(1-42) in APP\/PS1 mice.","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neulet.2014.06.010","volume":"578","author":"Xu S.","year":"2014","unstructured":"Xu S, Guan Q, Wang C, Wei X, Chen X, Zheng B, An P, Zhang J, Chang L, Zhou W, Mody I, Wang Q.  Rosiglitazone prevents the memory deficits induced by amyloid-beta oligomers  inhibition of inflammatory responses.","journal-title":"Neurosci Lett"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1097\/01.ASN.0000025786.87646.B1","volume":"13","author":"Cernuda-Moroll\u00f3n E.","year":"2002","unstructured":"Cernuda-Moroll\u00f3n E, Rodr\u00edguez-Pascual F, Klatt P, Lamas S, P\u00e9rez-Sala D.  PPAR agonists amplify iNOS expression while inhibiting NF-kappaB: implications for mesangial cell activation by cytokines.","journal-title":"J Am Soc Nephrol"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"14747","DOI":"10.1074\/jbc.M210819200","volume":"278","author":"Park E.J.","year":"2003","unstructured":"Park EJ, Park SY, Joe EH, Jou I.  15d-PGJ2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia.","journal-title":"J Biol Chem"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1073\/pnas.97.9.4844","volume":"97","author":"Straus D.S.","year":"2000","unstructured":"Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, Sengchanthalangsy LL, Ghosh G, Glass CK.  15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1523\/JNEUROSCI.20-15-05709.2000","volume":"20","author":"Lim G.P.","year":"2000","unstructured":"Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, Cole GM.  Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer\u2019s disease.","journal-title":"J Neurosci"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1523\/JNEUROSCI.23-20-07504.2003","volume":"23","author":"Yan Q.","year":"2003","unstructured":"Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL, Citron M, Landreth G.  Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer\u2019s disease.","journal-title":"J Neurosci"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/brain\/awh452","volume":"128","author":"Heneka M.T.","year":"2005","unstructured":"Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O\u2019Banion K, Klockgether T, Van Leuven F, Landreth GE.  Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice.","journal-title":"Brain"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/aps.2013.11","volume":"34","author":"Liu L.P.","year":"2013","unstructured":"Liu LP, Yan TH, Jiang LY, Hu W, Hu M, Wang C, Zhang Q, Long Y, Wang JQ, Li YQ, Hu M, Hong H.  Pioglitazone ameliorates memory deficits in streptozotocin-induced diabetic mice by reducing brain \u03b2-amyloid through PPAR\u03b3 activation.","journal-title":"Acta Pharmacol Sin"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1073\/pnas.0503839103","volume":"103","author":"Sastre M.","year":"2006","unstructured":"Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, Evert BO, Dumitrescu-Ozimek L, Thal DR, Landreth G, Walter J, Klockgether T, van Leuven F, Heneka MT.  Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=50","author":"Toledo E.M.","year":"2010","unstructured":"Toledo EM, Inestrosa NC."},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1172\/JCI18162","volume":"112","author":"Eriksen J.L.","year":"2003","unstructured":"Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE.  NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42","journal-title":"J Clin Invest"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"28737","DOI":"10.1074\/jbc.M115.675215","volume":"290","author":"Prade E.","year":"2015","unstructured":"Prade E, Bittner HJ, Sarkar R.  Lopez, Del, Amo, J.M.; Althoff-Ospelt, G.; Multhaup, G.; Hildebrand, P.W.; Reif, B. Structural mechanism of the interaction of alzheimer disease A\u03b2 fibrils with the non-steroidal anti-inflammatory drug (NSAID).","journal-title":"Sulindac Sulfide J Biol Chem"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1212\/01.WNL.0000149519.47454.F2","volume":"64","author":"Whitmer R.A.","year":"2005","unstructured":"Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K.  Midlife cardiovascular risk factors and risk of dementia in late life.","journal-title":"Neurology"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1042\/CS20150351","volume":"129","author":"Dias H.K.","year":"2015","unstructured":"Dias HK, Brown CL, Polidori MC, Lip GY, Griffiths HR.  LDL-lipids from patients with hypercholesterolaemia and Alzheimer\u2019s disease are inflammatory to microvascular endothelial cells: mitigation by statin intervention.","journal-title":"Clin Sci (Lond)"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"345","DOI":"10.18865\/ed.25.3.345","volume":"25","author":"Hendrie H.C.","year":"2015","unstructured":"Hendrie HC, Hake A, Lane K, Purnell C, Unverzagt F, Smith-Gamble V, Murrell J, Ogunniyi A, Baiyewu O, Callahan C, Saykin A, Taylor S, Hall K, Gao S.  Statin use, incident dementia and alzheimer disease in elderly african americans.","journal-title":"Ethn Dis"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1159\/000382128","volume":"73","author":"Liang T.","year":"2015","unstructured":"Liang T, Li R, Cheng O.  Statins for treating alzheimer\u2019s disease: Truly ineffective?","journal-title":"Eur Neurol"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000231980","volume":"28","author":"Solomon A.","year":"2009","unstructured":"Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA.  Midlife serum cholesterol and increased risk of Alzheimer\u2019s and vascular dementia three decades later.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1212\/WNL.0b013e3181feb2bf","volume":"75","author":"Mielke M.M.","year":"2010","unstructured":"Mielke MM, Zandi PP, Shao H, Waern M, \u00d6stling S, Guo X, Bj\u00f6rkelund C, Lissner L, Skoog I, Gustafson DR.  The 32-year relationship between cholesterol and dementia from midlife to late life.","journal-title":"Neurology"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1126\/science.1220725","volume":"335","author":"Strittmatter W.","year":"2012","unstructured":"Strittmatter W.  J. Medicine. Old drug, new hope for Alzheimer\u2019s disease.","journal-title":"Science"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2174\/156720501103140329220007","volume":"11","author":"Yin J.","year":"2014","unstructured":"Yin J, Turner GH, Coons SW, Maalouf M, Reiman EM, Shi J.  Association of amyloid burden, brain atrophy and memory deficits in aged apolipoprotein \u03b54 mice.","journal-title":"Curr Alzheimer Res"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.neuron.2008.04.010","volume":"58","author":"Jiang Q.","year":"2008","unstructured":"Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE.  ApoE promotes the proteolytic degradation of Abeta.","journal-title":"Neuron"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.bbalip.2010.02.010","volume":"1801","author":"Koldamova R.","year":"2010","unstructured":"Koldamova R, Fitz NF, Lefterov I.  The role of ATP-binding cassette transporter A1 in Alzheimer\u2019s disease and neurodegeneration.","journal-title":"Biochim Biophys Acta"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3233\/JAD-151020","volume":"51","author":"Bonet-Costa V.","year":"2016","unstructured":"Bonet-Costa V, Herranz-P\u00e9rez V, Blanco-Gand\u00eda M, Mas-Bargues C, Ingl\u00e9s M, Garcia-Tarraga P, Rodriguez-Arias M, Mi\u00f1arro J, Borras C, Garcia-Verdugo JM, Vi\u00f1a J.  Clearing amyloid-\u03b2 through PPAR\u03b3\/ApoE activation by genistein is a treatment of experimental alzheimer\u2019s disease.","journal-title":"J Alzheimers Dis"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.atherosclerosis.2009.01.008","volume":"205","author":"Ogata M.","year":"2009","unstructured":"Ogata M, Tsujita M, Hossain MA, Akita N, Gonzalez FJ, Staels B, Suzuki S, Fukutomi T, Kimura G, Yokoyama S.  On the mechanism for PPAR agonists to enhance ABCA1 gene expression.","journal-title":"Atherosclerosis"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/14728222.2011.594043","volume":"15","author":"Mandrekar-Colucci S.","year":"2011","unstructured":"Mandrekar-Colucci S, Landreth GE.  Nuclear receptors as therapeutic targets for Alzheimer\u2019s disease.","journal-title":"Expert Opin Ther Targets"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev-pathol-011110-130138","volume":"6","author":"Odegaard J.I.","year":"2011","unstructured":"Odegaard JI, Chawla A.  Alternative macrophage activation and metabolism.","journal-title":"Annu Rev Pathol"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI59903","volume":"122","author":"Talbot K.","year":"2012","unstructured":"Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE.  Demonstrated brain insulin resistance in Alzheimer\u2019s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.","journal-title":"J Clin Invest"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"889","DOI":"10.4239\/wjd.v5.i6.889","volume":"5","author":"Barbagallo M.","year":"2014","unstructured":"Barbagallo M, Dominguez LJ.  Type 2 diabetes mellitus and Alzheimer\u2019s disease.","journal-title":"World J Diabetes"},{"key":"ref=69","author":"Fehm H.L.","year":"2006","unstructured":"Fehm HL, Kern W, Peters A.","journal-title":"The selfish brain: competition for energy resources"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.bbagen.2009.08.002","volume":"1800","author":"Abramov A.Y.","year":"2010","unstructured":"Abramov AY, Duchen MR.  Impaired mitochondrial bioenergetics determines glutamate-induced delayed calcium deregulation in neurons.","journal-title":"Biochim Biophys Acta"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1113\/jphysiol.2012.230078","volume":"590","author":"Agrawal R.","year":"2012","unstructured":"Agrawal R, Gomez-Pinilla F.  \u2018Metabolic syndrome\u2019 in the brain: deficiency in omega-3 fatty acid exacerbates dysfunctions in insulin receptor signalling and cognition.","journal-title":"J Physiol"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40266-014-0228-7","volume":"32","author":"Liu J.","year":"2015","unstructured":"Liu J, Wang LN, Jia JP.  Peroxisome proliferator-activated receptor-gamma agonists for Alzheimer\u2019s disease and amnestic mild cognitive impairment: a systematic review and meta-analysis.","journal-title":"Drugs Aging"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.neurobiolaging.2009.10.009","volume":"32","author":"Sato T.","year":"2011","unstructured":"Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T.  Efficacy of PPAR-\u03b3 agonist pioglitazone in mild Alzheimer disease.","journal-title":"Neurobiol Aging"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"16725","DOI":"10.1523\/JNEUROSCI.2153-12.2012","volume":"32","author":"Denner L.A.","year":"2012","unstructured":"Denner LA, Rodriguez-Rivera J, Haidacher SJ, Jahrling JB, Carmical JR, Hernandez CM, Zhao Y, Sadygov RG, Starkey JM, Spratt H, Luxon BA, Wood TG, Dineley KT.  Cognitive enhancement with rosiglitazone links the hippocampal PPAR\u03b3 and ERK MAPK signaling pathways.","journal-title":"J Neurosci"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1523\/JNEUROSCI.4024-13.2014","volume":"34","author":"Jahrling J.B.","year":"2014","unstructured":"Jahrling JB, Hernandez CM, Denner L, Dineley KT.  PPAR\u03b3 recruitment to active ERK during memory consolidation is required for Alzheimer\u2019s disease-related cognitive enhancement.","journal-title":"J Neurosci"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3233\/JAD-2012-111661","volume":"30","author":"Searcy J.L.","year":"2012","unstructured":"Searcy JL, Phelps JT, Pancani T, Kadish I, Popovic J, Anderson KL, Beckett TL, Murphy MP, Chen KC, Blalock EM, Landfield PW, Porter NM, Thibault O.  Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer\u2019s disease.","journal-title":"J Alzheimers Dis"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1073\/pnas.0611314104","volume":"104","author":"Hort J.","year":"2007","unstructured":"Hort J, Lacz\u00f3 J, Vyhn\u00e1lek M, Bojar M, Bures J, Vlcek K.  Spatial navigation deficit in amnestic mild cognitive impairment.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/brain\/awn082","volume":"131","author":"Hoefer M.","year":"2008","unstructured":"Hoefer M, Allison SC, Schauer GF, Neuhaus JM, Hall J, Dang JN, Weiner MW, Miller BL, Rosen HJ.  Fear conditioning in frontotemporal lobar degeneration and Alzheimer\u2019s disease.","journal-title":"Brain"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.npep.2015.06.008","volume":"52","author":"Barage S.H.","year":"2015","unstructured":"Barage SH, Sonawane KD.  Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer\u2019s disease.","journal-title":"Neuropeptides"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s12640-013-9437-9","volume":"25","author":"Prakash A.","year":"2014","unstructured":"Prakash A, Kumar A.  Role of nuclear receptor on regulation of BDNF and neuroinflammation in hippocampus of \u03b2-amyloid animal model of Alzheimer\u2019s disease.","journal-title":"Neurotox Res"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.2042-7158.2011.01432.x","volume":"64","author":"Xiang G.Q.","year":"2012","unstructured":"Xiang GQ, Tang SS, Jiang LY, Hong H, Li Q, Wang C, Wang XY, Zhang TT, Yin L.  PPAR\u03b3 agonist pioglitazone improves scopolamine-induced memory impairment in mice.","journal-title":"J Pharm Pharmacol"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1161\/HYPERTENSIONAHA.107.103648","volume":"51","author":"Beyer A.M.","year":"2008","unstructured":"Beyer AM, Baumbach GL, Halabi CM, Modrick ML, Lynch CM, Gerhold TD, Ghoneim SM, de Lange WJ, Keen HL, Tsai YS, Maeda N, Sigmund CD, Faraci FM.  Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling.","journal-title":"Hypertension"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"9311","DOI":"10.1074\/jbc.R109.025031","volume":"285","author":"Ketsawatsomkron P.","year":"2010","unstructured":"Ketsawatsomkron P, Pelham CJ, Groh S, Keen HL, Faraci FM, Sigmund CD.  Does peroxisome proliferator-activated receptor-\u03b3 (PPAR \u03b3) protect from hypertension directly through effects in the vasculature?","journal-title":"J Biol Chem"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.3892\/mmr.2014.3113","volume":"11","author":"Di B.B.","year":"2015","unstructured":"Di BB, Li HW, Li WP, Shen XH, Sun ZJ, Wu X.  Pioglitazone inhibits high glucose-induced expression of receptor for advanced glycation end products in coronary artery smooth muscle cells.","journal-title":"Mol Med Rep"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"H39","DOI":"10.1152\/ajpheart.00490.2015","volume":"310","author":"Mukohda M.","year":"2016","unstructured":"Mukohda M, Stump M, Ketsawatsomkron P, Hu C, Quelle FW, Sigmund CD.  Endothelial PPAR-\u03b3 provides vascular protection from IL-1\u03b2-induced oxidative stress.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/FJC.0000000000000124","volume":"64","author":"Sakatani Y.","year":"2014","unstructured":"Sakatani Y, Miyoshi T, Oe H, Noda Y, Ohno Y, Nakamura K, Saito Y, Osawa K, Morita H, Kohno K, Ito H.  Pioglitazone prevents the endothelial dysfunction induced by ischemia and reperfusion in healthy subjects.","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"37006","DOI":"10.1074\/jbc.M700447200","volume":"282","author":"Fuenzalida K.","year":"2007","unstructured":"Fuenzalida K, Quintanilla R, Ramos P, Piderit D, Fuentealba RA, Martinez G, Inestrosa NC, Bronfman M.  Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis.","journal-title":"J Biol Chem"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1471-4159.2006.04393.x","volume":"101","author":"Haorah J.","year":"2007","unstructured":"Haorah J, Ramirez SH, Schall K, Smith D, Pandya R, Persidsky Y.  Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to blood-brain barrier dysfunction.","journal-title":"J Neurochem"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1038\/jcbfm.2008.59","volume":"28","author":"Fujimoto M.","year":"2008","unstructured":"Fujimoto M, Takagi Y, Aoki T, Hayase M, Marumo T, Gomi M, Nishimura M, Kataoka H, Hashimoto N, Nozaki K.  Tissue inhibitor of metalloproteinases protect blood-brain barrier disruption in focal cerebral ischemia.","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bbrc.2008.12.181","volume":"380","author":"Lee S.R.","year":"2009","unstructured":"Lee SR, Kim HY, Hong JS, Baek WK, Park JW.  PPARgamma agonist pioglitazone reduces matrix metalloproteinase-9 activity and neuronal damage after focal cerebral ischemia.","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1096\/fj.08-121624","volume":"23","author":"Huang W.","year":"2009","unstructured":"Huang W, Eum SY, Andr\u00e1s IE, Hennig B, Toborek M.  PPARalpha and PPARgamma attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities.","journal-title":"FASEB J"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4049\/jimmunol.1102942","volume":"189","author":"Sanz M.J.","year":"2012","unstructured":"Sanz MJ, Albertos F, Otero E, Juez M, Morcillo EJ, Piqueras L.  Retinoid X receptor agonists impair arterial mononuclear cell recruitment through peroxisome proliferator-activated receptor-\u03b3 activation.","journal-title":"J Immunol"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bcp.2014.07.018","volume":"92","author":"Wang L.","year":"2014","unstructured":"Wang L, Waltenberger B, Pferschy-Wenzig EM, Blunder M, Liu X, Malainer C, Blazevic T, Schwaiger S, Rollinger JM, Heiss EH, Schuster D, Kopp B, Bauer R, Stuppner H, Dirsch VM, Atanasov AG.  Natural product agonists of peroxisome proliferator-activated receptor gamma (PPAR\u03b3): a review.","journal-title":"Biochem Pharmacol"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/FJC.0000000000000143","volume":"64","author":"Wang P.","year":"2014","unstructured":"Wang P, Li B, Cai G, Huang M, Jiang L, Pu J, Li L, Wu Q, Zuo L, Wang Q, Zhou P.  Activation of PPAR-\u03b3 by pioglitazone attenuates oxidative stress in aging rat cerebral arteries through upregulating UCP2.","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40336-013-0026-y","volume":"1","author":"Mosconi L.","year":"2013","unstructured":"Mosconi L.  Glucose metabolism in normal aging and Alzheimer\u2019s disease: Methodological and physiological considerations for PET studies.","journal-title":"Clin Transl Imaging"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1212\/WNL.0000000000000432","volume":"82","author":"van der Ossenkoppele R.","year":"2014","unstructured":"van der Ossenkoppele R, Flier WM, Verfaillie SC, Vrenken H, Versteeg A, van Schijndel RA, Sikkes SA, Twisk J, Adriaanse SM, Zwan MD, Boellaard R, Windhorst AD, Barkhof F, Scheltens P, Lammertsma AA, van Berckel BN.  Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions.","journal-title":"Neurol"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.expneurol.2015.07.014","volume":"271","author":"De Nuccio C.","year":"2015","unstructured":"De Nuccio C, Bernardo A, Cruciani C, De Simone R, Visentin S, Minghetti L.  Peroxisome proliferator activated receptor-\u03b3 agonists protect oligodendrocyte progenitors against tumor necrosis factor-alpha-induced damage: Effects on mitochondrial functions and differentiation.","journal-title":"Exp Neurol"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/sj.tpj.6500397","volume":"7","author":"Roses A.D.","year":"2007","unstructured":"Roses AD, Saunders AM, Huang Y, Strum J, Weisgraber KH, Mahley RW.  Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer\u2019s disease).","journal-title":"Pharmacogenomics J"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.expneurol.2013.12.012","volume":"253","author":"Corona J.C.","year":"2014","unstructured":"Corona JC, de Souza SC, Duchen MR.  PPAR\u03b3 activation rescues mitochondrial function from inhibition of complex I and loss of PINK1.","journal-title":"Exp Neurol"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.neuroscience.2012.11.003","volume":"229","author":"Chiang M.C.","year":"2013","unstructured":"Chiang MC, Cheng YC, Lin KH, Yen CH.  PPAR\u03b3 regulates the mitochondrial dysfunction in human neural stem cells with tumor necrosis factor alpha.","journal-title":"Neuroscience"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.mito.2013.12.003","volume":"14","author":"Chiang M.C.","year":"2014","unstructured":"Chiang MC, Cheng YC, Chen HM, Liang YJ, Yen CH.  Rosiglitazone promotes neurite outgrowth and mitochondrial function in N2A cells  PPARgamma pathway.","journal-title":"Mitochondrion"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.yexcr.2004.01.002","volume":"295","author":"Quintanilla R.A.","year":"2004","unstructured":"Quintanilla RA, Orellana DI, Gonz\u00e1lez-Billault C, Maccioni RB.  Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5\/p35 pathway.","journal-title":"Exp Cell Res"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"e0123864","DOI":"10.1371\/journal.pone.0123864","volume":"10","author":"Chen J.","year":"2015","unstructured":"Chen J, Li S, Sun W, Li J.  Anti-diabetes drug pioglitazone ameliorates synaptic defects in AD transgenic mice by inhibiting cyclin-dependent kinase5 activity.","journal-title":"PLoS One"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1523\/JNEUROSCI.3413-13.2014","volume":"34","author":"Nenov M.N.","year":"2014","unstructured":"Nenov MN, Laezza F, Haidacher SJ, Zhao Y, Sadygov RG, Starkey JM, Spratt H, Luxon BA, Dineley KT, Denner L.  Cognitive enhancing treatment with a PPAR\u03b3 agonist normalizes dentate granule cell presynaptic function in Tg2576 APP mice.","journal-title":"J Neurosci"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3233\/JAD-151200","volume":"51","author":"Son S.M.","year":"2016","unstructured":"Son SM, Shin HJ, Byun J, Kook SY, Moon M, Chang YJ, Mook-Jung I.  Metformin facilitates amyloid-\u03b2 generation by \u03b2- and \u03b3-secretases  autophagy activation.","journal-title":"J Alzheimers Dis"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1750-1326-5-46","volume":"5","author":"Wang X.","year":"2010","unstructured":"Wang X, Zheng W, Xie JW, Wang T, Wang SL, Teng WP, Wang ZY.  Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model.","journal-title":"Mol Neurodegener"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.exger.2010.08.026","volume":"46","author":"Benedict C.","year":"2011","unstructured":"Benedict C, Frey WH, Schi\u00f6th HB, Schultes B, Born J, Hallschmid M.  Intranasal insulin as a therapeutic option in the treatment of cognitive impairments.","journal-title":"Exp Gerontol"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.nlm.2010.02.002","volume":"93","author":"McNay E.C.","year":"2010","unstructured":"McNay EC, Ong CT, McCrimmon RJ, Cresswell J, Bogan JS, Sherwin RS.  Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance.","journal-title":"Neurobiol Learn Mem"},{"key":"ref=109","first-page":"950","volume":"13","author":"Watson G.S.","year":"2005","unstructured":"Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S.  Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study.","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/sj.tpj.6500369","volume":"6","author":"Risner M.E.","year":"2006","unstructured":"Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD.  Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer\u2019s disease.","journal-title":"Pharmacogenomics J"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000054469","volume":"70","author":"Craft S.","year":"1999","unstructured":"Craft S, Asthana S, Schellenberg G, Cherrier M, Baker LD, Newcomer J, Plymate S, Latendresse S, Petrova A, Raskind M, Peskind E, Lofgreen C, Grimwood K.  Insulin metabolism in Alzheimer\u2019s disease differs according to apolipoprotein E genotype and gender.","journal-title":"Neuroendocrinology"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ana.10206","volume":"51","author":"Feinstein D.L.","year":"2002","unstructured":"Feinstein DL, Galea E, Gavrilyuk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, Landreth GE, Pershadsingh HA, Weinberg G, Heneka MT.  Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis.","journal-title":"Ann Neurol"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.pbb.2015.02.012","volume":"132","author":"Doost Mohammadpour J.","year":"2015","unstructured":"Doost Mohammadpour J, Hosseinmardi N, Janahmadi M, Fathollahi Y, Motamedi F, Rohampour K.  Non-selective NSAIDs improve the amyloid-\u03b2-mediated suppression of memory and synaptic plasticity.","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00702-014-1294-z","volume":"122","author":"Yu Y.","year":"2015","unstructured":"Yu Y, Li X, Blanchard J, Li Y, Iqbal K, Liu F, Gong CX.  Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice.","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.pbb.2012.03.028","volume":"102","author":"Gupta R.","year":"2012","unstructured":"Gupta R, Gupta LK.  Improvement in long term and visuo-spatial memory following chronic pioglitazone in mouse model of Alzheimer\u2019s disease.","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/ana.24439","volume":"78","author":"Heneka M.T.","year":"2015","unstructured":"Heneka MT, Fink A, Doblhammer G.  Effect of pioglitazone medication on the incidence of dementia.","journal-title":"Ann Neurol"},{"key":"ref=117","doi-asserted-by":"crossref","first-page":"e68612","DOI":"10.1371\/journal.pone.0068612","volume":"8","author":"Papadopoulos P.","year":"2013","unstructured":"Papadopoulos P, Rosa-Neto P, Rochford J, Hamel E.  Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer\u2019s disease with combined amyloid-\u03b2 and cerebrovascular pathology.","journal-title":"PLoS One"},{"key":"ref=118","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.bmcl.2014.12.073","volume":"25","author":"Flesch D.","year":"2015","unstructured":"Flesch D, Ness J, Lamers C, Dehm F, Popella S, Steri R, Ogorek I, Hieke M, Dannhardt G, Werz O, Weggen S, Schubert-Zsilavecz M.  SAR-studies of \u03b3-secretase modulators with PPAR\u03b3-agonistic and 5-lipoxygenase-inhibitory activity for Alzheimer\u2019s disease.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3233\/JAD-160656","volume":"55","author":"de la Monte S.M.","year":"2017","unstructured":"de la Monte SM, Tong M, Schiano I, Didsbury J.  Improved brain insulin\/IGF signaling and reduced neuroinflammation with T3D-959 in an experimental model of sporadic alzheimer\u2019s disease.","journal-title":"J Alzheimers Dis"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4172\/2161-0460.1000238","volume":"6","author":"Tong M.","year":"2016","unstructured":"Tong M, Dominguez C, Didsbury J, de la Monte SM.  Targeting alzheimer\u2019s disease Neuro-Metabolic Dysfunction with a small molecule nuclear receptor agonist (T3D-959) reverses disease pathologies.","journal-title":"J Alzheimers Dis Parkinsonism"},{"key":"ref=121","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.expneurol.2011.09.023","volume":"232","author":"Almad A.","year":"2011","unstructured":"Almad A, Lash AT, Wei P, Lovett-Racke AE, McTigue DM.  The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice.","journal-title":"Exp Neurol"},{"key":"ref=122","first-page":"45","volume":"68","author":"Geldmacher D.S.","year":"2011","unstructured":"Geldmacher DS, Fritsch T, McClendon MJ, Landreth G.  A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease.","journal-title":"Arch Neurol"},{"key":"ref=123","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000318845","volume":"30","author":"Gold M.","year":"2010","unstructured":"Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, Craft S, Landreth G, Linnam\u00e4gi U, Sawchak S.  Rosiglitazone monotherapy in mild-to-moderate Alzheimer\u2019s disease: results from a randomized, double-blind, placebo-controlled phase III study.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=124","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2174\/156720511796391935","volume":"8","author":"Harrington C.","year":"2011","unstructured":"Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, Saunders AM, Irizarry M, Jeter B, Zvartau-Hind M, van Dyck CH, Gold M.  Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer\u2019s disease: two phase 3 studies.","journal-title":"Curr Alzheimer Res"},{"key":"ref=125","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000371509","volume":"5","author":"Van Hildreth K.L.","year":"2015","unstructured":"Van Hildreth KL, Pelt RE, Moreau KL, Grigsby J, Hoth KF, Pelak V, Anderson CA, Parnes B, Kittelson J, Wolfe P, Nakamura T, Linnebur SA, Trujillo JM, Aquilante CL, Schwartz RS.  Effects of pioglitazone or exercise in older adults with mild cognitive impairment and insulin resistance: a pilot study.","journal-title":"Dement Geriatr Cogn Disord Extra"},{"key":"ref=126","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1755-5949.2012.00341.x","volume":"18","author":"Jiang L.Y.","year":"2012","unstructured":"Jiang LY, Tang SS, Wang XY, Liu LP, Long Y, Hu M, Liao MX, Ding QL, Hu W, Li JC, Hong H.  PPAR\u03b3 agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus.","journal-title":"CNS Neurosci Ther"},{"key":"ref=127","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3109\/00207454.2015.1015722","volume":"126","author":"Cheng H.","year":"2016","unstructured":"Cheng H, Shang Y, Jiang L, Shi TL, Wang L.  The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer\u2019s disease and mild-to-moderate Alzheimer\u2019s disease: a meta-analysis.","journal-title":"Int J Neurosci"},{"key":"ref=128","doi-asserted-by":"crossref","first-page":"9287","DOI":"10.1523\/JNEUROSCI.3348-08.2008","volume":"28","author":"Nicolakakis N.","year":"2008","unstructured":"Nicolakakis N, Aboulkassim T, Ongali B, Lecrux C, Fernandes P, Rosa-Neto P, Tong XK, Hamel E.  Complete rescue of cerebrovascular function in aged Alzheimer\u2019s disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist.","journal-title":"J Neurosci"},{"key":"ref=129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1750-1326-3-9","volume":"3","author":"Inestrosa N.C.","year":"2008","unstructured":"Inestrosa NC, Toledo EM.  The role of Wnt signaling in neuronal dysfunction in Alzheimer\u2019s Disease.","journal-title":"Mol Neurodegener"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/164907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T08:33:15Z","timestamp":1558341195000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/164907\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,14]]},"references-count":129,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,2,14]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x16666180828100002","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2,14]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-01-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}